Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

AIM OF THE STUDY: Newly approved therapies with high and uncertain budget impact pose challenges to public health care systems worldwide. One recent example is chimeric antigen receptor T cell (CAR-T) therapies for adults with large B-cell lymphoma (LBCL). This study’s primary objective is to exami...

Full description

Bibliographic Details
Main Authors: Maria Trottmann, Eva Blozik, Marcel Hilbig, Daniel LoVerdi, Marcello Pedruzzi, Tina Scherer, Martina Weiss, Mark Pletscher, Niklaus Meier
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2023-09-01
Series:Swiss Medical Weekly
Online Access:https://smw.ch/index.php/smw/article/view/3441

Similar Items

Similar Items